PRT2527

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
274 patients (estimated)
Sponsors
Prelude Therapeutics
Collaborators
BeiGene
Tags
Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
Trial Type
Treatment
Last Update
3 weeks ago
SparkCures ID
1989
NCT Identifier
NCT05665530

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.